Open Beta
TREN
MetriLume
TREN

US marketsINMB

SEC-sourced researchBeta

INMB

Inmune Bio, Inc.

Company comparison ↗

Data passport

CIK
0001711754
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Sep 23, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 14,000.0000 USD; December 2025: 50,000.0000 USD50K USD0 USD0December 2024December 2025
INMB · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202414,000.0000Mar 30, 2026
December 202550,000.0000Mar 30, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202550,000.0000-45,933,000.0000-22,582,000.000032,351,000.00008,827,000.0000Mar 30, 2026
December 202414,000.0000-42,082,000.0000-33,361,000.000039,562,000.00007,465,000.0000Mar 30, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$50KDecember 2025Mar 30, 202610-K
Previous period revenueRevenues$14KDecember 2024Mar 30, 202610-K
Net incomeNetIncomeLoss-$45.93MDecember 2025Mar 30, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$22.58MDecember 2025Mar 30, 202610-K
Total assetsAssets$32.35MDecember 2025Mar 30, 202610-K
Total liabilitiesLiabilities$8.83MDecember 2025Mar 30, 202610-K

New filings

Explore methodology ↗